※ 新薬開発科で実施している治験（第I相試験）情報です。
治験を「キーワード」から探す
キーワードから探す
実施中の治験
| NCT番号 | 他の登録番号 | 治験名 | 製薬企業（治験依頼者） | 治験責任医師 | |
|---|---|---|---|---|---|
| TBD | TBD | 新規Phase 1治験 2025年10月 Central IRB審議予定 | TBD |  |
|
| TBD | TBD | 新規Phase 1治験 2025年9月 Central IRB審議予定 | TBD | |
|
| TBD | TBD | 新規Phase 1治験 2025年8月 Central IRB審議予定 | TBD | |
|
| NCT05907980 | jRCT2031230072 | A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors | Chugai Pharma USA, Inc. | 清水俊雄 | |
| NCT05005403 | jRCT2031210386 | A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab | AbbVie | 生駒龍興 | |
| NCT06858813 | EU CT ID 2024-518012-39 | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer | AbbVie | 清水俊雄 | |
| NCT06586515 | jRCT2041240103 | A First-in-Human Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Eli Lilly | 清水俊雄 | |
| NCT06806852 | jRCT2011240074 | A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | Boehringer Ingelheim | 清水俊雄 | |
| NCT05875168 | jRCT2031230233 | Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors | Daiichi-Sankyo | 清水俊雄 | |
| NCT05836324 | jRCT2031240610 | A First-in-Human Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Incyte | 清水俊雄 | |
Towards “Five-Stars” Phase 1 Center of Excellence
Department of New Experimental Therapeutics
Early-Phase 1 Drug Development Service